Association Between US Drug Price and Measures of Efficacy for Oncology Drugs Approved by the US Food and Drug Administration From 2015 to 2020

Miloš D Miljkovic; Jordan E Tuia; Timothée Olivier; Alyson Haslam; Vinay Prasad

doi:10.1001/jamainternmed.2022.4924

Association Between US Drug Price and Measures of Efficacy for Oncology Drugs Approved by the US Food and Drug Administration From 2015 to 2020

JAMA Intern Med. 2022 Dec 1;182(12):1319-1320. doi: 10.1001/jamainternmed.2022.4924.

Authors

Miloš D Miljkovic¹, Jordan E Tuia², Timothée Olivier^{2

3}, Alyson Haslam², Vinay Prasad^{2

4}

Affiliations

¹ Cartesian Therapeutics, Gaithersburg, Maryland.
² Department of Epidemiology and Biostatistics, University of California, San Francisco.
³ Department of Oncology, Geneva University Hospital, Geneva, Switzerland.
⁴ Department of Medicine, University of California, San Francisco.

No abstract available

Plain language summary

This cross-sectional study estimates all US Food and Drug Administration anticancer approvals in recent years and evaluates if an association exists between their cost and efficacy.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents* / therapeutic use
Drug Approval
Humans
Neoplasms* / drug therapy
United States
United States Food and Drug Administration

Substances

Antineoplastic Agents